Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.

Zhou, Xueyin; Ren, Ting; Zan, Hongyuan; Hua, Chunyan; Guo, Xufeng

Zhou, Xueyin; Ren, Ting; Zan, Hongyuan; Hua, Chunyan; Guo, Xufeng.

Afiliação

Zhou X; School of Medicine, Wenzhou Medical University, Wenzhou, China.
Ren T; Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Zan H; School of Medicine, Wenzhou Medical University, Wenzhou, China.
Hua C; School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Guo X; Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

Front Immunol ; 13: 864202, 2022.

Article em En | MEDLINE | ID: mdl-35669786

Assuntos

Neoplasias Esofágicas; Receptor de Morte Celular Programada 1; Biomarcadores; Neoplasias Esofágicas/tratamento farmacológico; Humanos; Inibidores de Checkpoint Imunológico; Imunoterapia/métodos; Receptor de Morte Celular Programada 1/metabolismo

Palavras-chave

LAG-3; TIGIT; TIM-3; biomarker; esophageal cancer; immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Receptor de Morte Celular Programada 1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google